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Most of the key effectors of apoptosis are constitutively
expressed in cells and ready to operate; however, activation
of diverse transcription factors (TFs), specific for noxious
conditions, eventually leads to alteration of the transcriptome
and expression of proapoptotic proteins. Several recent
reports pointed at NF-Y as yet another TF having
a – previously unsuspected – role in the process. The obvious
question – pro or anti? – is more difficult to answer, as the
current data delineate a regulatory tale, rather than a
simplistic ‘good versus bad guy’ script.
NF-Y is a heterotrimer composed of two histone-fold
domain (HFD)-subunits NF-YB/NF-YC and of NF-YA, which
provides the capacity to bind avidly to the CCAAT sequence in
transcriptional regulatory regions.1 NF-YA is the limiting
subunit of the complex, tightly regulated by post-translational
modifications (PTMs) of lysines; acetylation by the coactivator
KAT3 protects NF-YA from polyubiquitination-mediated
degradation, prolonging an otherwise relative short half-life.2
Gurtner et al.3 tried to stably overexpress NF-YA in cells, an
experiment bound to failure, including in our hands. Rather
than giving up, they went on showing that cells undergo
apoptosis, and most importantly, that this can be corrected by
transfecting fibroblasts, genetically ablated of E2F1 or p53.
Apparently, a rather modest increase of E2F1, whose
expression is under NF-Y control, is believed to drive the
process. So, toomuch NF-Y, or NF-YA in this case, is bad, but
what about too little? Imbriano and co-workers4 functionally
ablated the three subunits by shRNA interference and found
that NF-YA elimination leads to a remarkable apoptotic
response. The suicide is preceded by a delay in S-phase
progression, which unleashes p53 activation and a DNA-
damage response. These data are in agreement with previous
mouse genetic data obtained with KO technology; embry-
ogenesis was stopped very early, with cells affected by severe
defects in S-phase progression.5 On the other hand,
inactivation of NF-YB or NF-YC caused a different defect,
namely a delay in G2/M exit,4 which is quite surprising,
considering that all subunits are required for DNA-binding.
The difference might have to do with separate roles of NF-YA
and the HFD dimer in DNA metabolism, related to specific
groups of genes whose transcription might be differentially
sensitive to depletion of the single subunits. What do we know
about the genes regulated by NF-Y?
Thanks to ChIP-on-chip, profilings and bioinformatic
analysis, the NF-Y regulome is relatively well understood,1
by and large, pro-survival, pro-growth genes are found aplenty
and the anti-apoptotic BI-1, Bcl-xl and Bcl-2 are controlled
directly.6 Interestingly, there is a difference in the transcrip-
tome upon NF-YA or NF-YB inactivations; in the latter, the
most notable term in GO analysis is cell cycle, among which
G2/M genes stand out,4,6 in line with the notorious abundance
of CCAAT boxes in G2/M promoters.1 This is very well in
keeping with the phenotypic effects of shRNA inactivation.
Genes inhibited by NF-YA inactivation, instead, mostly belong
to metabolism terms, which is not immediately translatable
into a phenotype of S-phase progression impairment, nor
activation of the DNA-damage response.4 In general, it is far
from apparent to discern an enrichment of proapoptotic terms
among genes controlled by NF-Y. The expression of
proapoptotic CCAAT-less Bax, PUMA, NOXA and BIK is
increased upon NF-YB removal, suggesting an indirect effect,
which is indeed essentially absent in p53/ cells.6 Collec-
tively, these data would argue that NF-Y positively controls an
antiapoptotic program and that the overexpression/inactiva-
tion effects are secondary to the activation of other TFs
(Figure 1).
There are, however, important caveats to this interpreta-
tion. The first came from ChIP-on-chip assays showing that
NF-Y is associated not only to active, but also to inactive loci,
which are activated after NF-Y removal; interestingly,
apoptosis was one of the few terms that popped up in GO
analysis of this repressed subset.7 The second comes from a
recent report on transcriptional control of Bim, a strong
proapototic gene, essential to mediate cell death of sympa-
thetic neurons upon NGF withdrawal. Ham and co-workers8
showed that increased Bim transcription is the result of
cooperation between FOXO3 and NF-Y, to recruit the KAT3
coactivator.9 Finally, findings of Emerson and co-workers10
made the matter even more intriguing; by dissecting the p53-
mediated activation of the proapoptotic Fas/APO1 gene
promoter, they could not find a classic p53 responsive
element, but stumbled on an NF-Y site, instead. In fact, the
site is very degenerate and found in an unusual location,
downstream of the transcriptional start site rather than in the
typical 80 area. In essence, such deviant site(s) would go
completely unnoticed in a TFBS inspection of promoters, even
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with the upgraded NF-Y PSFM we recently introduced.1 The
obvious question is, therefore, how many deviant NF-Y sites
in proapoptotic genes are being missed simply because of
their unorthodox location and/or sequence. Note that previous
examples of CCAAT degeneracy almost certainly points at the
necessity to accommodate an overlapping site for another
TF.1 In summary, NF-Y proapoptotic primary target genes
exist, and the cohort is likely larger and more genetically
diversified than previously thought; connections with specific
TFs, direct or allowing binding to adjacent sites, are probably
equally crucial. Another important aspect of the Morachis
et al.10 paper is that activation of Fas/APO1 through NF-Y/p53
is temporarily delayed, but longer lasting with respect to p21,
which functions on bona fide p53REs. The activatory scenario
is different from previous findings on the repressive role of p53
on cell-cycle promoters of the G2/M phase,11 shared by p63
and p73,12,13 but it does explain the data of NF-YA over-
expressions,2 reinstating the importance of the ‘special’
partnership between NF-Y and p53.6
Notmuch is known about the NF-Y-p53 combination of sites
at the genomic level, but CCAAT and E2F elements are
emerging in important pathways. First, bioinformatic analysis
of all RefSeq CCAAT promoters for TFBS enrichments
indicates E2F as very high in the ranking, particularly in cell
cycle promoters.1 Second, profilings of primary cells
undergoing an in vitro transformation process by p53 and
p16INK4A inactivation identified a G2/M genes signature,
whose architecture relied upon NF-Y and E2F sites.14 Third,
de novo motifs discovery in promoters of large cohorts of
genes overexpressed in different tumors led to the identifica-
tion of a core of three TF sites: the NF-Y and E2F duo
(Figure 1), and surprisingly, p53.15 Clearly, precise ChIP-Seq
inspection of the mutual locations is now required to further
detail the interplay of NF-Y with specific E2F family members.
The proapoptotic table is crowded with additional stress-
specific TFs, whose altered expression and/or function is
notoriously associated with apoptosis. The promoters of
CHOP and XBP1, masters of the ER-stress response, of
HSFs (heat shock response) of HIF-1a (hypoxia) as well as of
p53/p63, have a CCAAT in a ‘perfect’ location and are under
transcriptional control of NF-Y1(RM, unpublished, Figure 1).
The ER-stress genetic program is a good example of a
coordinated response, collectively activated by ATF4/ATF6,
XBP1 and Gadd153/CHOP/DDIT3.16–18 All these TFs func-
tion on a landscape predisposed by NF-Y binding16 (refer-
ences therein). Eventually, damaged cells are committed to
cell death, which is mediated by the same TFs. ATF6 and
XBP1 are mainly controlled at the post-transcriptional level,
whereas CHOP/DDIT3 is activated transcriptionally in the
initial phases of the response, and it is the key mediator of
apoptosis.18 A recent paper illustrates the strategic connec-
tions leading to a global response; cisplatin treatment of
squamous cell carcinomas activates ATM-mediated p63
phosphorylation which, in turn, causes a proapoptotic
response by activation of CHOP transcription via tethering
of phospho-p63 on the CCAAT/NF-Y complex of the CHOP
promoter.19 Profiling and ChIP-on-chip analysis demon-
strated a widespread presence of CCAAT boxes in activated
genes, and the relative NF-Y binding, in promoters regulated
by phospho-p63. Many promoters of the DNA-damage and
ER-stress response are bound by NF-Y under ‘basal’,
uninduced conditions,16,20 and cooperation with pathway-
specific TFs has been shown in many downstream targets.1
In summary, a better understanding of the role of NF-Y in
apoptosis will come from a more detailed genomic analysis of
NF-Y sites, positive and negative, and the matching with the
regulomes of fellow TFs involved in apoptosis induction. A
structural understanding of the interactions with p53 and
members of the family, and possibly E2Fs, might explain why
NF-YA inactivation is sensed as an immediate DNA-damage
danger by the cells. Finally, an additional, untapped layer of
complexity resides in the structural and PTM features of the
HFDdimer; whether the pro- or antiapoptotic behavior of NF-Y
is locally influenced by specific PTMs of the HFD subunits, still
very much a black box at the moment, or NF-YA for that
matter, is an appealing possibility.
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Figure 1 The arrows connect NF-Y to TFs involved in the different processes.
Dotted line refers to indirect activation/repression through CCAAT boxes by p53/
p63/p73. The line between NF-Y and p53/p63/p73 indicates a direct interaction
between the TFs
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